Clinical trials: First Pregnancy
Premature Birth
Evaluation of Immunization Coverage of Premature Infants Leaving CHU d'Angers According to the Recommended Regimen During the First 4 Months (VACCIPREM)
Premature children are particularly vulnerable in terms of infection and vaccinated in a specific, reinforced vaccination schedule.
- Trial name
- VACCIPREM (NCT03918096)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 384 people
- Sponsor
- University Hospital, Angers
Renal Cell Carcinoma
Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
Evaluation of unfavourable outcome-related factors in patients affected by renal cell cancer in treatment with everolimus and previously treated with a Vascular endothelial growth factor (VEGF) inhibitor (i.e.
- Trial name
- ORCHIDEE (NCT02338570)
- Testing
- Everolimus
- Where
- 8 sites in Italy
- Volunteers
- 31 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Pregnancy, Health Literacy
Mobile Assisted Education on Prenatal Health
This study aims to evaluate the effect of mobile-assisted education on prenatal health literacy, health behaviors, and childbirth outcomes among primigravida women
- Conditions
- Pregnancy, Health Literacy, Mobile Assisted Education, Health Behavior
- Trial name
- NCT07900152
- Testing
- Mobile-Assisted Education
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Benha University
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Ovarian Neoplasms, Fallopian Tube Neoplasms
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
It has been reported that antiangiogenic drugs combined with chemotherapy as first-line treatment, and subsequent antiangiogenic drugs as maintenance therapy for ovarian cancer can achieve better clinical benefits.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
- Trial name
- NCT04807166
- Testing
- Drug: Anlotinib, Drug: Carboplatin/Paclitaxel
- Where
- 6 sites in China
- Volunteers
- 56 people
- Sponsor
- Wenjun Cheng
Healthy, Gestational Diabetes Mellitus
Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study
This observational study is designed to determine how sugars, lipids and proteins in breast milk vary among mothers; is affected by maternal diet, health and microbiota and vary over the course of lactation.
- Conditions
- Healthy, Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- NCT01817127
- Where
- United States
- Volunteers
- 395 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Ovary Cancer
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
The purpose of this study is to evaluate the feasibility and toxicity of the combination of paclitaxel, carboplatin, and topotecan in patients with previously untreated, stage III or IV epithelial ovarian carcinoma or primary…
- Trial name
- NCT00193297
- Testing
- Topotecan, Paclitaxel, Carboplatin
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Primigravida Labour
Obstetric Outcomes of Primigravidae
To determine obstetric outcomes in primigravida at term at women's health centre
- Trial name
- NCT06784505
- Volunteers
- 100 people
- Sponsor
- Assiut University
Clear Cell Renal Carcinoma
Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
The therapeutic scenario of metastatic renal cancer is undergoing a new revolution with the appearance of a novel therapeutic strategy after the antiangiogenic treatments, that is the immunotherapy, in addition to the approval of…
- Trial name
- INMUNOSUN (NCT03066427)
- Testing
- Sunitinib
- Where
- 9 sites in Spain
- Volunteers
- 23 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
CARE1 Pragmatic Clinical Trial
Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI)…
- Trial name
- CARE1 (NCT06364631)
- Testing
- Nivolumab, Ipilimumab, Pembrolizumab
- Where
- 46 sites in Austria, Czechia and 2 more
- Volunteers
- 1,250 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Uterine Fibroids - 1St Diagnosis, Uterine Fibroids Affecting Pregnancy
Holistic Medicine Treatment of Uterine Fibroids-Adults
This clinical trial aims to evaluate the efficacy of holistic medicine treatments for unmarried women ("Bachelorettes") residing on U.S.
- Conditions
- Uterine Fibroids - 1St Diagnosis, Uterine Fibroids Affecting Pregnancy, Uterine Fibroid Degenerated
- Trial name
- HMTXUFAdult (NCT07219381)
- Testing
- Holistic Medicine (HM)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Virtual Tribunal Monastery
Metastatic Disease, Renal Cell Carcinoma
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
The ROSORC trial is a randomized study comparing the efficacy of a new association (sorafenib and IL-2) versus the standard therapy (sorafenib) in patients affected by different histotypes of metastatic RCC.
- Trial name
- ROSORC (NCT00609401)
- Testing
- Nexavar (Sorafenib), IL-2
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Italian Trial in Medical Oncology
Ovarian Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
- Trial name
- NCT07278336
- Testing
- ABBV-901, Bevacizumab, Carboplatin
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 285 people
- Sponsor
- AbbVie
Renal Cell Carcinoma
A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
This is an open-label, single arm , Ib/II phase trial to evaluate the efficacy and safety of AK112（ivonescimab）monotherapy as first-line treatment for favourable risk advanced/metastatic renal cell carcinoma (a/m RCC).
- Trial name
- NCT06472895
- Testing
- AK112 monotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Steroid-Sensitive Nephrotic Syndrome
Study of Initial Steroid Treatment in Young Children With Nephrotic Syndrome
This study is a multicentric, prospective, randomized, double blind, placebo controlled trial compared the efficacy of 6 months vs.
- Trial name
- NCT04536181
- Testing
- Prednisolone
- Where
- 4 sites in China
- Sponsor
- Children's Hospital of Fudan University
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Renal Cell Carcinoma, Kidney Cancer
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
Advanced renal cell carcinoma is invariably fatal, with a life expectancy of 2-3 years since diagnosis. Sunitinib is the standard first-line treatment for this condition, but it is associated to multiple side effects, with…
- Trial name
- QUASAR (NCT02446795)
- Testing
- Sunitinib, Isoquercetin
- Where
- 5 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Consorzio Oncotech
Luteal Phase, Biomarkers
Early Pregnancy Cohort and Preimplantation Factor
Miscarriage is a common event associated with severe psychological and social morbidity, further tormenting in women suffering recurrent pregnancy loss (RPL) by at least three consecutive losses.
- Conditions
- Luteal Phase, Biomarkers, Abortion, Spontaneous, Abortion, Habitual
- Trial name
- PEP-cohort (NCT02761772)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Nordsjaellands Hospital
Ovarian Cancer, Epithelial
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
- Trial name
- CHIMOVIP (NCT03025477)
- Testing
- CC0 - Carboplatin (IV) - Paclitaxel (IV), CC0 - Cisplatin (IP) - Epirubicin (IV), CC>0 - Carboplatin (IV)- Paclitaxel (IV)
- Where
- 7 sites in France
- Volunteers
- 84 people
- Sponsor
- Groupe Hospitalier Diaconesses Croix Saint-Simon
Breastfeeding
Effect of Breastfeeding Training
Breast milk is a unique, natural and universal food with excellent content that ensures healthy growth and development of the baby.
- Trial name
- Breastfeeding (NCT04752787)
- Testing
- Online breastfeeding training, QR code supported online breastfeeding training
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Sakarya University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.